

# Call for Partnership


Dear Sir or Madam,

for the last decade, JOANNEUM RESEARCH HEALTH has been pioneering the use of our proprietary dermal Open Flow Microperfusion (dOFM™) technology to support the translational development of dermal drug products. By obtaining pharmacokinetic and pharmacodynamic data at or near the sites of action in skin, dOFM™ studies have been able to rapidly derisk/endorse drug development decisions.

We are now seeking a limited number of clinical partners to adopt the dOFM™ development approach. We encourage you to visit our website for further details and to submit your letter of interest until December 31st, 2022 here:

[Call for Partnership](#)

Kind regards,  
Joanneum Research HEALTH  
[clinical.partner@joanneum.at](mailto:clinical.partner@joanneum.at)



## Call for Partnership

We would like to invite qualified institutes and organizations to become certified clinical dOFM™ partners. Visit our website to learn how you can participate in this unique opportunity.

[More](#)

## EUFEPS Meeting

Our Vice President Frank Sinner will be attending the Global Bioequivalence Harmonization Initiative on September 28-29, 2022 to present on our new dOFM™ partnership model.

[More](#)



## dOFM™ Webinar

Watch our webinar „Informed decisions in dermal drug development with dOFM™ to learn more about our membrane-free, time-resolved, minimally-invasive, in-vivo sampling technology.

[More](#)

## References

Use of OFM in BE study. Bodenlenz, M., Tiffner, K.I., Raml, R., Augustin, T., Dragatin, C., Birngruber, T., Schimek, D., Schwagerle, G., Pieber, T.R., Raney, S.G., Kanfer, I., Sinner, F., 2017. Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence. Clin. Pharmacokinet. 56, 91–98. [DOI](#)

OFM use shown for antibody PK. Dragatin, C., Polus, F., Bodenlenz, M., Calonder, C., Aigner, B., Tiffner, K.I., Mader, J.K., Ratzner, M., Woessner, R., Pieber, T.R., Cheng, Y., Loesche, C., Sinner, F., Bruin, G., 2016. Secukinumab distributes into dermal interstitial fluid of psoriasis patients as demonstrated by open flow microperfusion. Exp. Dermatol. 25, 157–159. [DOI](#)

OFM mentioned in FDA report as research highlight. US FDA - Center for drug evaluation and research, 2021. FY 2020 GDUFA Science and Research Report. [Link](#)

Are you looking for a long-term, synergetic partnership? We are open to innovative proposals to create win-win agreements and take dOFM™ to the next level.

PDF Download

JOANNEUM RESEARCH  
Forschungsgesellschaft mbH  
Leonhardstraße 59  
8010 Graz, Austria

phone: +43 316 876-0  
[prm@joanneum.at](mailto:prm@joanneum.at)

Visit us on



[Imprint](#)

You can [edit your newsletter settings](#) or [unsubscribe completely](#).

[\*\*Unsubscribe\*\*](#)